论文部分内容阅读
采用随机交叉试验设计,将20例T2DM患者随机分成治疗组和对照组,治疗组:早晚餐前应用诺和锐30皮下注射;对照组:早晚餐前半小时应用诺和灵30R皮下注射。参比血糖调整胰岛素剂量。结果:两组均能降低空腹及餐后血糖,锐30低血糖发生1例,灵30R发生3例,两组午餐后血糖降低欠佳。结论两组均能有效控制25小时血糖,锐30较灵30R更有效降低餐后血糖漂移,减少了低血糖事件发生。
Twenty patients with T2DM were randomly divided into treatment group and control group by randomized crossover design. The treatment group was given subcutaneous injection of Novo-Rui-Rui 30 before and after meals. The control group was injected subcutaneously with Novo-30R for half an hour before breakfast and dinner. Reference blood glucose to adjust insulin dose. Results: Both fasting and postprandial blood glucose were decreased in both groups, one in Rui 30 hypoglycemia and one in Ling 30R. Both groups had poor hypoglycemia after lunch. Conclusion Both groups can effectively control 25 hours of blood glucose, Rui 30 than Ling 30R more effective in reducing postprandial blood glucose drift, reducing the incidence of hypoglycemia.